IBDEI054 ; ; 12-JAN-2012
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;JAN 12, 2012
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,99) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,6657,0)
 ;;=282.62^^59^428^100
 ;;^UTILITY(U,$J,358.3,6657,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,6657,1,4,0)
 ;;=4^282.62
 ;;^UTILITY(U,$J,358.3,6657,1,5,0)
 ;;=5^Sickle-Cell With Crisis
 ;;^UTILITY(U,$J,358.3,6657,2)
 ;;=^267982
 ;;^UTILITY(U,$J,358.3,6658,0)
 ;;=281.1^^59^428^110
 ;;^UTILITY(U,$J,358.3,6658,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,6658,1,4,0)
 ;;=4^281.1
 ;;^UTILITY(U,$J,358.3,6658,1,5,0)
 ;;=5^Vit B12 Deficiency(Dietary)
 ;;^UTILITY(U,$J,358.3,6658,2)
 ;;=^267974
 ;;^UTILITY(U,$J,358.3,6659,0)
 ;;=286.7^^59^428^44
 ;;^UTILITY(U,$J,358.3,6659,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,6659,1,4,0)
 ;;=4^286.7
 ;;^UTILITY(U,$J,358.3,6659,1,5,0)
 ;;=5^Coagulation Defect(Any),Acquired
 ;;^UTILITY(U,$J,358.3,6659,2)
 ;;=^2235
 ;;^UTILITY(U,$J,358.3,6660,0)
 ;;=289.9^^59^428^106
 ;;^UTILITY(U,$J,358.3,6660,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,6660,1,4,0)
 ;;=4^289.9
 ;;^UTILITY(U,$J,358.3,6660,1,5,0)
 ;;=5^Thrombocytosis, Essential
 ;;^UTILITY(U,$J,358.3,6660,2)
 ;;=^55344
 ;;^UTILITY(U,$J,358.3,6661,0)
 ;;=451.9^^59^428^107
 ;;^UTILITY(U,$J,358.3,6661,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,6661,1,4,0)
 ;;=4^451.9
 ;;^UTILITY(U,$J,358.3,6661,1,5,0)
 ;;=5^Thrombophlebitis 
 ;;^UTILITY(U,$J,358.3,6661,2)
 ;;=^93357
 ;;^UTILITY(U,$J,358.3,6662,0)
 ;;=446.6^^59^428^108
 ;;^UTILITY(U,$J,358.3,6662,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,6662,1,4,0)
 ;;=4^446.6
 ;;^UTILITY(U,$J,358.3,6662,1,5,0)
 ;;=5^Thrombotic Thrombocytopenic Purpura(Ttp)
 ;;^UTILITY(U,$J,358.3,6662,2)
 ;;=^119061
 ;;^UTILITY(U,$J,358.3,6663,0)
 ;;=286.4^^59^428^111
 ;;^UTILITY(U,$J,358.3,6663,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,6663,1,4,0)
 ;;=4^286.4
 ;;^UTILITY(U,$J,358.3,6663,1,5,0)
 ;;=5^Von Willebrand'S Disease
 ;;^UTILITY(U,$J,358.3,6663,2)
 ;;=^127267
 ;;^UTILITY(U,$J,358.3,6664,0)
 ;;=204.00^^59^428^4
 ;;^UTILITY(U,$J,358.3,6664,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,6664,1,4,0)
 ;;=4^204.00
 ;;^UTILITY(U,$J,358.3,6664,1,5,0)
 ;;=5^All, W/O Remission
 ;;^UTILITY(U,$J,358.3,6664,2)
 ;;=^267521
 ;;^UTILITY(U,$J,358.3,6665,0)
 ;;=204.01^^59^428^3
 ;;^UTILITY(U,$J,358.3,6665,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,6665,1,4,0)
 ;;=4^204.01
 ;;^UTILITY(U,$J,358.3,6665,1,5,0)
 ;;=5^All, In Remission
 ;;^UTILITY(U,$J,358.3,6665,2)
 ;;=^267522
 ;;^UTILITY(U,$J,358.3,6666,0)
 ;;=204.10^^59^428^41
 ;;^UTILITY(U,$J,358.3,6666,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,6666,1,4,0)
 ;;=4^204.10
 ;;^UTILITY(U,$J,358.3,6666,1,5,0)
 ;;=5^Cll, W/O Remission
 ;;^UTILITY(U,$J,358.3,6666,2)
 ;;=^267523
 ;;^UTILITY(U,$J,358.3,6667,0)
 ;;=204.11^^59^428^40
 ;;^UTILITY(U,$J,358.3,6667,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,6667,1,4,0)
 ;;=4^204.11
 ;;^UTILITY(U,$J,358.3,6667,1,5,0)
 ;;=5^Cll, In Remission
 ;;^UTILITY(U,$J,358.3,6667,2)
 ;;=^267524
 ;;^UTILITY(U,$J,358.3,6668,0)
 ;;=201.90^^59^428^71
 ;;^UTILITY(U,$J,358.3,6668,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,6668,1,4,0)
 ;;=4^201.90
 ;;^UTILITY(U,$J,358.3,6668,1,5,0)
 ;;=5^Hodgkin'S Lymphoma, Unpsec Type & Site
 ;;^UTILITY(U,$J,358.3,6668,2)
 ;;=^267430
 ;;^UTILITY(U,$J,358.3,6669,0)
 ;;=785.6^^59^428^77
 ;;^UTILITY(U,$J,358.3,6669,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,6669,1,4,0)
 ;;=4^785.6
 ;;^UTILITY(U,$J,358.3,6669,1,5,0)
 ;;=5^Lymphadenopathy
 ;;^UTILITY(U,$J,358.3,6669,2)
 ;;=^72368
 ;;^UTILITY(U,$J,358.3,6670,0)
 ;;=200.20^^59^428^78
 ;;^UTILITY(U,$J,358.3,6670,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,6670,1,4,0)
 ;;=4^200.20
 ;;^UTILITY(U,$J,358.3,6670,1,5,0)
 ;;=5^Lymphoma, Burkitt'S, Unspecified Sites
 ;;^UTILITY(U,$J,358.3,6670,2)
 ;;=^17529
 ;;^UTILITY(U,$J,358.3,6671,0)
 ;;=202.00^^59^428^80
 ;;^UTILITY(U,$J,358.3,6671,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,6671,1,4,0)
 ;;=4^202.00
 ;;^UTILITY(U,$J,358.3,6671,1,5,0)
 ;;=5^Lymphoma, Low-Grade, Unspec Site
 ;;^UTILITY(U,$J,358.3,6671,2)
 ;;=^72606
 ;;^UTILITY(U,$J,358.3,6672,0)
 ;;=200.10^^59^428^79
 ;;^UTILITY(U,$J,358.3,6672,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,6672,1,4,0)
 ;;=4^200.10
 ;;^UTILITY(U,$J,358.3,6672,1,5,0)
 ;;=5^Lymphoma, Int Or High Grade, Unspec Site
 ;;^UTILITY(U,$J,358.3,6672,2)
 ;;=^175886
 ;;^UTILITY(U,$J,358.3,6673,0)
 ;;=273.3^^59^428^81
 ;;^UTILITY(U,$J,358.3,6673,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,6673,1,4,0)
 ;;=4^273.3
 ;;^UTILITY(U,$J,358.3,6673,1,5,0)
 ;;=5^Macroglobulinemia
 ;;^UTILITY(U,$J,358.3,6673,2)
 ;;=^73013
 ;;^UTILITY(U,$J,358.3,6674,0)
 ;;=203.00^^59^428^90
 ;;^UTILITY(U,$J,358.3,6674,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,6674,1,4,0)
 ;;=4^203.00
 ;;^UTILITY(U,$J,358.3,6674,1,5,0)
 ;;=5^Multiple Myeloma W/O Rem
 ;;^UTILITY(U,$J,358.3,6674,2)
 ;;=^267514
 ;;^UTILITY(U,$J,358.3,6675,0)
 ;;=203.01^^59^428^89
 ;;^UTILITY(U,$J,358.3,6675,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,6675,1,4,0)
 ;;=4^203.01
 ;;^UTILITY(U,$J,358.3,6675,1,5,0)
 ;;=5^Multiple Myeloma In Remission
 ;;^UTILITY(U,$J,358.3,6675,2)
 ;;=^267515
 ;;^UTILITY(U,$J,358.3,6676,0)
 ;;=238.6^^59^428^93
 ;;^UTILITY(U,$J,358.3,6676,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,6676,1,4,0)
 ;;=4^238.6
 ;;^UTILITY(U,$J,358.3,6676,1,5,0)
 ;;=5^Plasmacytoma Nos
 ;;^UTILITY(U,$J,358.3,6676,2)
 ;;=^81973
 ;;^UTILITY(U,$J,358.3,6677,0)
 ;;=205.00^^59^428^6
 ;;^UTILITY(U,$J,358.3,6677,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,6677,1,4,0)
 ;;=4^205.00
 ;;^UTILITY(U,$J,358.3,6677,1,5,0)
 ;;=5^Aml, W/O Remission
 ;;^UTILITY(U,$J,358.3,6677,2)
 ;;=^267531
 ;;^UTILITY(U,$J,358.3,6678,0)
 ;;=205.01^^59^428^5
 ;;^UTILITY(U,$J,358.3,6678,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,6678,1,4,0)
 ;;=4^205.01
 ;;^UTILITY(U,$J,358.3,6678,1,5,0)
 ;;=5^Aml, In Remission
 ;;^UTILITY(U,$J,358.3,6678,2)
 ;;=^267532
 ;;^UTILITY(U,$J,358.3,6679,0)
 ;;=205.10^^59^428^43
 ;;^UTILITY(U,$J,358.3,6679,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,6679,1,4,0)
 ;;=4^205.10
 ;;^UTILITY(U,$J,358.3,6679,1,5,0)
 ;;=5^Cml, W/O Remission
 ;;^UTILITY(U,$J,358.3,6679,2)
 ;;=^267533
 ;;^UTILITY(U,$J,358.3,6680,0)
 ;;=205.11^^59^428^42
 ;;^UTILITY(U,$J,358.3,6680,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,6680,1,4,0)
 ;;=4^205.11
 ;;^UTILITY(U,$J,358.3,6680,1,5,0)
 ;;=5^Cml, In Remission
 ;;^UTILITY(U,$J,358.3,6680,2)
 ;;=^267534
 ;;^UTILITY(U,$J,358.3,6681,0)
 ;;=289.0^^59^428^45
 ;;^UTILITY(U,$J,358.3,6681,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,6681,1,4,0)
 ;;=4^289.0
 ;;^UTILITY(U,$J,358.3,6681,1,5,0)
 ;;=5^Erthryocytosis, Secondary
 ;;^UTILITY(U,$J,358.3,6681,2)
 ;;=^186856
 ;;^UTILITY(U,$J,358.3,6682,0)
 ;;=238.4^^59^428^94
 ;;^UTILITY(U,$J,358.3,6682,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,6682,1,4,0)
 ;;=4^238.4
 ;;^UTILITY(U,$J,358.3,6682,1,5,0)
 ;;=5^Polycytheria Rubra Vera
 ;;^UTILITY(U,$J,358.3,6682,2)
 ;;=^96105
 ;;^UTILITY(U,$J,358.3,6683,0)
 ;;=V58.61^^59^428^112
 ;;^UTILITY(U,$J,358.3,6683,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,6683,1,4,0)
 ;;=4^V58.61
 ;;^UTILITY(U,$J,358.3,6683,1,5,0)
 ;;=5^Warfarin/Coumadin Use
 ;;^UTILITY(U,$J,358.3,6683,2)
 ;;=Warfarin/Coumadin Use^303459
 ;;^UTILITY(U,$J,358.3,6684,0)
 ;;=282.49^^59^428^104
 ;;^UTILITY(U,$J,358.3,6684,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,6684,1,4,0)
 ;;=4^282.49
 ;;^UTILITY(U,$J,358.3,6684,1,5,0)
 ;;=5^Thalassemia Nec
 ;;^UTILITY(U,$J,358.3,6684,2)
 ;;=^329910
 ;;^UTILITY(U,$J,358.3,6685,0)
 ;;=289.89^^59^428^13
 ;;^UTILITY(U,$J,358.3,6685,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,6685,1,4,0)
 ;;=4^289.89
 ;;^UTILITY(U,$J,358.3,6685,1,5,0)
 ;;=5^Blood Diseases Nec
 ;;^UTILITY(U,$J,358.3,6685,2)
 ;;=^329887
 ;;^UTILITY(U,$J,358.3,6686,0)
 ;;=238.79^^59^428^76
 ;;^UTILITY(U,$J,358.3,6686,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,6686,1,4,0)
 ;;=4^238.79
 ;;^UTILITY(U,$J,358.3,6686,1,5,0)
 ;;=5^LYMPH/HEMATPOITC TIS NEC
 ;;^UTILITY(U,$J,358.3,6686,2)
 ;;=^334033
 ;;^UTILITY(U,$J,358.3,6687,0)
 ;;=287.30^^59^428^95
 ;;^UTILITY(U,$J,358.3,6687,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,6687,1,4,0)
 ;;=4^287.30
 ;;^UTILITY(U,$J,358.3,6687,1,5,0)
 ;;=5^Primary Thrombocytopenia
 ;;^UTILITY(U,$J,358.3,6687,2)
 ;;=^332841
 ;;^UTILITY(U,$J,358.3,6688,0)
 ;;=288.09^^59^428^2
 ;;^UTILITY(U,$J,358.3,6688,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,6688,1,4,0)
 ;;=4^288.09
 ;;^UTILITY(U,$J,358.3,6688,1,5,0)
 ;;=5^Agranulocytosis
 ;;^UTILITY(U,$J,358.3,6688,2)
 ;;=^334042
 ;;^UTILITY(U,$J,358.3,6689,0)
 ;;=V10.21^^59^428^51
 ;;^UTILITY(U,$J,358.3,6689,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,6689,1,4,0)
 ;;=4^V10.21
 ;;^UTILITY(U,$J,358.3,6689,1,5,0)
 ;;=5^H/O Laryngeal Cancer
 ;;^UTILITY(U,$J,358.3,6689,2)
 ;;=^295214
 ;;^UTILITY(U,$J,358.3,6690,0)
 ;;=284.2^^59^428^91
 ;;^UTILITY(U,$J,358.3,6690,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,6690,1,4,0)
 ;;=4^284.2
 ;;^UTILITY(U,$J,358.3,6690,1,5,0)
 ;;=5^Myelophthisic Anemia (code cond 1st)
 ;;^UTILITY(U,$J,358.3,6690,2)
 ;;=^334037
 ;;^UTILITY(U,$J,358.3,6691,0)
 ;;=202.40^^59^428^64
 ;;^UTILITY(U,$J,358.3,6691,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,6691,1,4,0)
 ;;=4^202.40
 ;;^UTILITY(U,$J,358.3,6691,1,5,0)
 ;;=5^Hairy Cell Leukemia,Unspecified site
 ;;^UTILITY(U,$J,358.3,6691,2)
 ;;=^69587
 ;;^UTILITY(U,$J,358.3,6692,0)
 ;;=287.49^^59^428^105
 ;;^UTILITY(U,$J,358.3,6692,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,6692,1,4,0)
 ;;=4^287.49
 ;;^UTILITY(U,$J,358.3,6692,1,5,0)
 ;;=5^Thrombocytopenia,Drug Induced
 ;;^UTILITY(U,$J,358.3,6692,2)
 ;;=^339610
 ;;^UTILITY(U,$J,358.3,6693,0)
 ;;=465.9^^59^429^69
 ;;^UTILITY(U,$J,358.3,6693,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,6693,1,4,0)
 ;;=4^465.9
 ;;^UTILITY(U,$J,358.3,6693,1,5,0)
 ;;=5^URI
 ;;^UTILITY(U,$J,358.3,6693,2)
 ;;=URI^269878
 ;;^UTILITY(U,$J,358.3,6694,0)
 ;;=462.^^59^429^59
 ;;^UTILITY(U,$J,358.3,6694,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,6694,1,4,0)
 ;;=4^462.
 ;;^UTILITY(U,$J,358.3,6694,1,5,0)
 ;;=5^Sore Throat
